共 86 条
- [1] Trépo C(2014)Hepatitis B virus infection Lancet 384 2053-2063
- [2] Chan HLY(2004)Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 1521-1531
- [3] Lok A(2013)Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection Hepatology 58 98-107
- [4] Liaw YF(2014)Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B—a nationwide cohort study Gastroenterology 147 143-151.e5
- [5] Sung JJY(2009)Hepatitis B virus resistance to nucleos(t)ide analogues Gastroenterology 137 1593-608.e1
- [6] Chow WC(2005)Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine Hepatology 42 121-129
- [7] Hosaka T(2007)Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present Antimicrob Agents Chemother 51 902-911
- [8] Suzuki F(2008)Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance Hepatology 47 1473-1482
- [9] Kobayashi M(2016)Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial Gut 65 852-860
- [10] Wu CY(2017)No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg− patients with chronic hepatitis B after 8 years of treatment J Viral Hepat 24 68-74